Effectiveness and tolerability of camrelizumab combined with molecular targeted therapy for patients with unresectable or advanced HCC.

Cancer Immunol Immunother · 2023 · PMC10264531 · PMID 36840762

Europe PMC DOI

hedged sentence

0.0550

closest p · 1.1× alpha

0.0550

boldest claim

The sentences

showed a trendp = 0.055so close (0.05 < p ≤ 0.1)

Patients with AFP ≥ 400 ng/mL showed a trend of poor survival compared to patients with AFP < 400 ng/mL (median OS: 12.9 vs. 14.1 months; p = 0.055) (Fig. 3 c).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.